Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Research output: Contribution to journalArticlepeer-review


  • Yvette Drew
  • Jonathan Ledermann
  • Geoff Hall
  • Ros Glasspool
  • Martin Highley
  • Gordon Jayson
  • Julieann Sludden
  • James Murray
  • David Jamieson
  • Sarah Halford
  • Gary Acton
  • Zoe Backholer
  • Raffaella Mangano
  • Alan Boddy
  • Nicola Curtin
  • Ruth Plummer


Original languageEnglish
Pages (from-to)e21
JournalBritish Journal of Cancer
Issue number12
Early online date22 Mar 2016
Publication statusPublished - 14 Jun 2016

Sustainable Development Goals